The chemotherapeutic strategy with a novel NF-kappa B inhibitor in bladder cancer

点击翻译按钮获取中文摘要

The present study was undertaken to assess the possibility of enhancement of chemosensitivity to CPT-11 by a novel and strong NF-κB inhibitor, DHMEQ in bladder cancer. Constitutive activation of NF-κB was observed in KU19-19 cells. NF-κB was activated by the treatment with SN38. However, pretreatment with DHMEQ inhibited the activation of NF-κB induced by SN-38. The combination treatment resulted in a significantly higher level of growth inhibition compared to treatment with DHMEQ or SN-38 alone. Chemotherapy in combination with DHMEQ might be a novel therapeutic modality against bladder cancer.